Lin Ming-Tzer, Lin Hsien-Ho, Lee Pei-Lin, Weng Pei-Hsuan, Lee Chang-Chun, Lai Ting-Chun, Liu Wei, Chen Chi-Ling
Department of Internal Medicine, Hsiao Chung-Cheng Hospital, No. 15-1, Sec. 1, Nanya South Road, Banciao District, New Taipei, 220, Taiwan.
Sleep Breath. 2015 Sep;19(3):809-17. doi: 10.1007/s11325-014-1082-x. Epub 2014 Nov 25.
Dyslipidemia is considered as one mechanism causing cardiovascular sequelae in obstructive sleep apnea (OSA). Continuous positive airway pressure (CPAP) can reduce cardiovascular morbidities but its effect on lipid profiles is inconclusive. This study aimed to investigate the effects of CPAP on lipid profiles by a meta-analysis of the existing randomized controlled trials.
Studies were retrieved from MEDLINE/PubMed, EMBASE, CENTRAL, commercial websites, and article references up to August 2013 following the protocols (PROSPERO CRD42012002636). Randomized controlled trials investigating the CPAP effects on changes in lipid profiles in adult patients with OSA were included. Two independent researchers extracted relevant data in duplicate. The pooled effect was analyzed by fixed-effect generic inverse variance, and the heterogeneity was assessed using the I (2) statistic.
Six trials with 348 patients and 351 controls were included. CPAP significantly lowered total cholesterol (mean, -6.23 mg/dl; 95% CI, -8.73 to -3.73; I (2), 0%; p < 0.001), triglyceride (mean, -12.60 mg/dl; 95% CI, -18.80 to -6.41; I (2), 25%; p < 0.001), and high-density lipoprotein (mean, -1.05 mg/dl; 95% CI, -1.69 to -0.40; I (2), 0%; p = 0.001), but not low-density lipoprotein (mean, -1.01 mg/dl; 95% CI, -5.04 to 3.02; I (2), 0%; p = 0.62). The lipid-lowering effects were homogeneous across the studies. By subgroup analysis, the reductions of lipid profiles were associated with the cross-over design, subtherapeutic CPAP as placebo, enrolled patients with moderate-to-severe OSA or daytime sleepiness, and CPAP treatment with short-term duration or good compliance.
This meta-analysis validates the observation that CPAP can reduce lipid profiles in patients with OSA.
血脂异常被认为是阻塞性睡眠呼吸暂停(OSA)导致心血管后遗症的一种机制。持续气道正压通气(CPAP)可降低心血管疾病发病率,但其对血脂水平的影响尚无定论。本研究旨在通过对现有随机对照试验的荟萃分析,探讨CPAP对血脂水平的影响。
按照研究方案(PROSPERO CRD42012002636),从MEDLINE/PubMed、EMBASE、CENTRAL、商业网站及截至2013年8月的文章参考文献中检索相关研究。纳入调查CPAP对成年OSA患者血脂水平变化影响的随机对照试验。两名独立研究人员重复提取相关数据。采用固定效应通用逆方差分析合并效应,并使用I²统计量评估异质性。
纳入6项试验,共348例患者和351例对照。CPAP显著降低总胆固醇(均值,-6.23mg/dl;95%CI,-8.73至-3.73;I²,0%;p<0.001)、甘油三酯(均值,-12.60mg/dl;95%CI,-18.80至-6.41;I²,25%;p<0.001)和高密度脂蛋白(均值,-1.05mg/dl;95%CI,-1.69至-0.40;I²,0%;p = 0.001),但对低密度脂蛋白无显著影响(均值,-1.01mg/dl;95%CI,-5.04至3.02;I²,0%;p = 0.62)。各研究的降脂效果具有同质性。亚组分析显示,血脂水平降低与交叉设计、作为安慰剂的亚治疗性CPAP、纳入中重度OSA或白天嗜睡患者以及短期或依从性良好的CPAP治疗有关。
本荟萃分析证实了CPAP可降低OSA患者血脂水平这一观察结果。